Search global stocks & ETFs...Ctrl K
Learn Mode
DXCM
Stock Profile
07-28
Recommended Metric
Score Card
Explore Scores Tab
4.36
Very Good
Valuation Score
Key Score
2.00
Bad
Management
3.00
Average
Growth
2.00
Bad
Profitability
5.00
Very Good
Fin. Health
2.00
Bad
Dividends
--
--
Analyst
2.00
Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$73.16
Baseline
High
$117.60
▲
60.74%
Avg
$86.52
▲
18.26%
Low
$67.67
▼
-7.50%
Analyst Ratings based on 37 Analysts
Strong Buy
1541%
Buy
1746%
Hold
514%
Sell
000%
Strong Sell
000%
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 11,000 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. The company enables people to take control of health through innovative biosensing technology. The G7 is an integrated continuous glucose monitoring system. Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes. The G7 and G7 15 Day includes finger stick elimination, continuous glucose readings and others.Read More
Stock News
View All Updates
News100%Bullish
1 Cash-Producing Stock with Impressive Fundamentals and 2 We Find Risky
4hYahoo
DXCM Receives FDA Clearance for Stelo OTC CGM System for Children
7hYahoo
DXCM Receives FDA Clearance for Stelo OTC CGM System for Children
7hZacks
Abbott's CGM Growth Story Stays Intact Despite Q1 Moderation
7hZacks
Here's Why DexCom (DXCM) is a Strong Growth Stock
7hZacks
Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor
1dBenzinga
Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $88
1dBenzinga
FDA Clears First Over-The-Counter Continuous Glucose Monitor For Children
4dBenzinga
DexCom Expands Beyond CGMs With CONNECT Results AI Apps And Nutrisense Deal
4dYahoo
3 Reasons Investors Love DexCom (DXCM)
5dYahoo
TD Cowen Maintains Buy on DexCom, Raises Price Target to $95
6dBenzinga
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
6dYahoo
Mizuho Maintains Outperform on DexCom, Raises Price Target to $85
1wBenzinga
DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes
1wYahoo
Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes
1wBenzinga
DexCom Inc (NASDAQ:DXCM) Passes Rigorous Quality Screen with Strong Profitability and Growth Metrics
1wChartMill
Inspire Medical: Golden Opportunity To Monetize A Fundamentally Mispriced Selloff
1wSeekingAlpha
Reported Saturday, Dexcom CONNECT Trial Shows G7 Delivers 1.6% Average A1C Reduction In Type 2 Diabetes Patients Not Using Insulin Over 26 Weeks
1wBenzinga
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
1wYahoo
Assessing DexCom (DXCM) Valuation After Recent Share Price Momentum
1wYahoo
Is DexCom Stock Underperforming the Dow?
1wYahoo
Stifel Maintains Buy on DexCom, Raises Price Target to $90
1wBenzinga
Dexcom buys Nutrisense; Insulet rolls out patch pump update
1wYahoo
Here's Why You Should Retain DexCom Stock in Your Portfolio
1wYahoo
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
1wYahoo
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
1wYahoo
DexCom To Present New Data And Announce Strategic Business Initiatives At American Diabetes Association's Scientific Sessions In New Orleans, June 5-8
1wBenzinga
Tandem Diabetes Valuation: Is 1.1x Sales a Buy?
1wYahoo
Did FDA-App Recalls and Activist Pressure Just Rewire Dexcom’s (DXCM) Software-Driven Investment Narrative?
1wYahoo
2 Growth Stocks to Buy and Hold for a Decade
2wYahoo
TNDM Stock: What to Know About Tandem's 2026 Reset
2wYahoo
Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
2wYahoo
Citigroup Maintains Buy on DexCom, Raises Price Target to $84
2wBenzinga
Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners
2wYahoo
U.S.-Iran strikes, Snowflake soars, Robinhood's new AI tools and more in Morning Squawk
2wCNBC
Signos CEO talks using AI to power its drug-free weight loss tool
2wCNBC
How The DexCom (DXCM) Investment Story Is Shifting With New Guidance And Valuation Resets
2wYahoo
Signos raises $20M, expands Dexcom partnership for weight loss
2wYahoo
Signos, Inc., Maker of the First FDA-cleared CGM System for Weight Management, Raises $20 Million to Accelerate Growth
2wYahoo
Signos grows foothold in weight loss wave fueled by GLP-1s with its AI health data tracking
2wCNBC
Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users
3wYahoo
DexCom Reveals Stolen Lots Of Scrapped Dexcom G7 Sensors Were Sold And Used By Customers, Launches Investigation With FDA And Authorities To Protect Patient Safety
3wBenzinga
S&P 500 Posts Eighth Consecutive Weekly Gain Led by Health Care, Utilities
3wYahoo
QuantumCore Announces Changes to Board of Directors
3wYahoo
DexCom Flex Launch Targets Wider Type 2 Market With Valuation Upside
3wYahoo
Here's How Much You Would Have Made Owning DexCom Stock In The Last 15 Years
3wBenzinga
Harnessing medtech market alliances, ŌURA sets IPO plans in motion
3wYahoo
Analysts Upgrade DexCom (DXCM) to “Outperform,” Driving Share Recovery
3wYahoo
DexCom Might Finally Be Cheap Enough
3wSeekingAlpha
Live Longer and Better. Does Medicine’s New Obsession Really Work?
3wYahoo